Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers

Neurology

Volumn 84, Issue 4, 2015, Pages 399-406

  Helmich, Rick C ^a,b   Thaler, Avner ^c,e   Van Nuenen, Bart F L ^f   Gurevich, Tanya ^c,e   Mirelman, Anat ^c   Marder, Karen S ^g   Bressman, Susan ^h   Orr Urtreger, Avi ^d,e   Giladi, Nir ^c,e   Bloem, Bastiaan R ^b   Toni, Ivan ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

^c Department of Neurology   (Netherlands)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

^f CATHARINA HOSPITAL   (Netherlands)

^g NewYork Presbyterian Hospital   (United States)

^h BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONNECTOME; CONTROLLED STUDY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MUTATION; HETEROZYGOTE; HUMAN; MALE; PARIETAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RISK FACTOR; AGE; FUNCTIONAL NEUROIMAGING; GENETICS; MIDDLE AGED; MUTATION; NERVE TRACT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PATHOPHYSIOLOGY; PRODROMAL SYMPTOM;

ADULT; AGE FACTORS; AGED; FEMALE; FUNCTIONAL NEUROIMAGING; HETEROZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NEURAL PATHWAYS; PARIETAL LOBE; PARKINSON DISEASE; PRODROMAL SYMPTOMS; PROTEIN-SERINE-THREONINE KINASES; PUTAMEN;

EID: 84927605772     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001189     Document Type: Article

References (40)

1. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-2431.
2. Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006;443:768-773.
3. Brück A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study. Mov Disord 2006;21:958-963.
4. Mounayar S, Boulet S, Tande D, et al. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 2007;130:2898-2914.
5. Helmich RC, Derikx LC, Bakker M, Scheeringa R, Bloem BR, Toni I. Spatial remapping of cortico-striatal connectivity in Parkinson's disease. Cereb Cortex 2010; 20:1175-1186.
6. Poulopoulos M, Levy OA, Alcalay RN. The neuropathology of genetic Parkinson's disease. Mov Disord 2012;27: 831-842.
7. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
8. Mirelman A, Heman T, Yasinovsky K, et al. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation. Mov Disord 2013;28:1683-1690.
9. Thaler A, Mirelman A, Helmich RC, et al. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. Cortex 2013;49:2501-2511.
10. Van Nuenen BFL, Helmich RC, Ferraye M, et al. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. Brain 2012;135:3687-3698.
11. Hulihan MM, Ishihara-Paul L, Kachergus J, et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 2008;7: 591-594.
12. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005;76:672-680.
13. Marder K, Tang M, Alcalay R, et al. Age specific penetrance of the LRRK2 G2019S mutation in the Michael J. Fox Ashkenazi Jewish (AJ) LRRK2 Consortium. Neurology 2014;82(suppl):S17.002. Abstract.
14. Gan-Or Z, Giladi N, Rozovski U, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 2008;70:2277-2283.
15. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 2007;8:700-711.
16. Postuma RB, Dagher A. Basal ganglia functional connectivity based on a meta-analysis of 126 positron emission tomography and functional magnetic resonance imaging publications. Cereb Cortex 2005;16:1508-1521.
17. Lund TE, Nørgaard MD, Rostrup E, Rowe JB, Paulson OB. Motion or activity: their role in intra-and inter-subject variation in fMRI. NeuroImage 2005;26:960-964.
18. Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE, Penny WD. Statistical Parametric Mapping: The Analysis of Functional Brain Images. Waltham, MA: Academic Press; 2011.
19. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.
20. Draganski B, Kherif F, Kloppel S, et al. Evidence for segregated and integrative connectivity patterns in the human basal ganglia. J Neurosci 2008;28:7143-7152.
21. Di Martino A, Scheres A, Margulies D, et al. Functional connectivity of human striatum: a resting state fMRI study. Cereb Cortex 2008;18:2735-2747.
22. Goldwurm S, Tunesi S, Tesei S, et al. Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease. Mov Disord 2011;26:2144-2145.
23. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011; 69:193-197.
24. Thaler A, Mirelman A, Gurevich T, et al. Lower cognitive performance in healthy G2019S LRRK2 mutation carriers. Neurology 2012;79:1027-1032.
25. Sierra M, Sánchez-Juan P, Martínez-Rodríguez MI, et al. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease. Neurology 2013; 80:621-626.
26. Nandhagopal R, Mak E, Schulzer M, et al. Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology 2008;71:1790-1795.
27. Adams JR, Van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005;128:2777-2785.
28. Li X, Patel JC, Wang J, et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 2010;30:1788-1797.
29. Gharbawie OA, Stepniewska I, Qi H, Kaas JH. Multiple parietal-frontal pathways mediate grasping in macaque monkeys. J Neurosci 2011;31:11660-11677.
30. Samuel M, Ceballos-Baumann AO, Blin J, et al. Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements: a PET study. Brain 1997;120:963-976.
31. Lehericy S, Ducros M, Krainik M, et al. 3-D diffusion tensor axonal tracking shows distinct SMA and pre-SMA projections to the human striatum. Cereb Cortex 2004;14: 1302-1309.
32. Hacker CD, Perlmutter JS, Criswell SR, Ances BM, Snyder AZ. Resting state functional connectivity of the striatum in Parkinson's disease. Brain 2012;135:3699-3711.
33. Bergman H, Feingold A, Nini A, et al. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci 1998;21:32-38.
34. Baumer T, Pramstaller PP, Siebner HR, et al. Sensorimotor integration is abnormal in asymptomatic Parkin mutation carriers: a TMS study. Neurology 2007;69:1976-1981.
35. Pessiglione M, Czernecki V, Pillon B, et al. An effect of dopamine depletion on decision-making: the temporal coupling of deliberation and execution. J Cogn Neurosci 2005;17:1886-1896.
36. Reetz K, Tadic V, Kasten M, et al. Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiol Dis 2010;39:402-408.
37. Brockmann K, Gröger A, Di Santo A, et al. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers. Mov Disord 2011;26:2335-2342.
38. Bezard E. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003;26: 215-221.
39. van Nuenen BFL, Helmich RC, Buenen N, Van De Warrenburg BPC, Bloem BR, Toni I. Compensatory activity in the extrastriate body area of Parkinson's disease patients. J Neurosci 2012;32:9546-9553.
40. Cramer SC, Sur M, Dobkin BH, et al. Harnessing neuroplasticity for clinical applications. Brain 2011;134:1591-1609.